Dominic Paquin-Proulx

List of Publications by Year
in descending order

53	1,689	257357	315616
papers	citations	24 h-index	38 g-index

58	58	58	3548
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Anti-HIV antibody development up to 1 year after antiretroviral therapy initiation in acute HIV infection. Journal of Clinical Investigation, 2022, 132, .	3.9	9
2	A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates. Science Translational Medicine, 2022, 14, .	5.8	73
3	Dynamics of ILâ€15/ILâ€15Râ€Î± expression in response to HSVâ€1 infection reveal a novel mode of viral immune evasion counteracted by iNKT cells. European Journal of Immunology, 2022, 52, 462-471.	1.6	2
4	A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model. Vaccines, 2022, 10, 717.	2.1	15
5	Anti-V2 antibodies virus vulnerability revealed by envelope V1 deletion in HIV vaccine candidates. IScience, 2021, 24, 102047.	1.9	16
6	Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors. Frontiers in Immunology, 2021, 12, 682120.	2.2	9
7	Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	44
8	A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge. Npj Vaccines, 2021, 6, 129.	2.9	47
9	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. Nature Immunology, 2021, 22, 1503-1514.	7.0	40
10	Preferential and persistent impact of acute HIV-1 infection on CD4⁺iNKT cells in colonic mucosa. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	2
11	Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge. PLoS Pathogens, 2020, 16, e1008764.	2.1	37
12	Longitudinal Analysis of Peripheral and Colonic CD161+ CD4+ T Cell Dysfunction in Acute HIV-1 Infection and Effects of Early Treatment Initiation. Viruses, 2020, 12, 1426.	1.5	3
13	Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nature Medicine, 2020, 26, 498-501.	15.2	43
14	Impact of the expression system on the immune responses to self-assembling protein nanoparticles (SAPNs) displaying HIV-1 V1V2 loop. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 29, 102255.	1.7	5
15	Dynamic MAIT cell response with progressively enhanced innateness during acute HIV-1 infection. Nature Communications, 2020, 11, 272.	5.8	38
16	RV144 HIV-1 vaccination impacts post-infection antibody responses. PLoS Pathogens, 2020, 16, e1009101.	2.1	13
17	MicroRNAs 145 and 148a Are Upregulated During Congenital Zika Virus Infection. ASN Neuro, 2019, 11, 175909141985098.	1.5	24
18	Colony-stimulating factor-1- and interleukin-34-derived macrophages differ in their susceptibility to Mycobacterium marinum. Journal of Leukocyte Biology, 2019, 106, 1257-1269.	1.5	16

#	Article	IF	Citations
19	Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet HIV,the, 2019, 6, e297-e306.	2.1	73
20	IL13RÎ±2 expression identifies tissueâ€resident ILâ€22â€producing PLZF⁺ innate TÂcells in the human liver. European Journal of Immunology, 2018, 48, 1329-1335.	1.6	13
21	Dicer-2 Regulates Resistance and Maintains Homeostasis against Zika Virus Infection in Drosophila. Journal of Immunology, 2018, 201, 3058-3072.	0.4	41
22	Human interleukin-34-derived macrophages have increased resistance to HIV-1 infection. Cytokine, 2018, 111, 272-277.	1.4	13
23	Limited immune surveillance in lymphoid tissue by cytolytic CD4+ T cells during health and HIV disease. PLoS Pathogens, 2018, 14, e1006973.	2.1	30
24	Latent Mycobacterium tuberculosis Infection Is Associated With a Higher Frequency of Mucosal-Associated Invariant T and Invariant Natural Killer T Cells. Frontiers in Immunology, 2018, 9, 1394.	2.2	33
25	Biomimetic Placenta-Fetus Model Demonstrating Maternalâ€“Fetal Transmission and Fetal Neural Toxicity of Zika Virus. Annals of Biomedical Engineering, 2018, 46, 1963-1974.	1.3	28
26	Severely Impaired Control of Bacterial Infections in a Patient With Cystic Fibrosis Defective in Mucosal-Associated Invariant T Cells. Chest, 2018, 153, e93-e96.	0.4	26
27	A flow cytometry based assay that simultaneously measures cytotoxicity and monocyte mediated antibody dependent effector activity. Journal of Immunological Methods, 2018, 462, 74-82.	0.6	19
28	MAIT cells are activated in acute Dengue virus infection and after in vitro Zika virus infection. PLoS Neglected Tropical Diseases, 2018, 12, e0006154.	1.3	38
29	MAIT cells reside in the female genital mucosa and are biased towards IL-17 and IL-22 production in response to bacterial stimulation. Mucosal Immunology, 2017, 10, 35-45.	2.7	178
30	Bacteroides are associated with GALT iNKT cell function and reduction of microbial translocation in HIV-1 infection. Mucosal Immunology, 2017, 10, 69-78.	2.7	40
31	Vitamin D treatment modulates immune activation in cystic fibrosis. Clinical and Experimental Immunology, 2017, 189, 359-371.	1.1	51
32	Clinical impact of vitamin D treatment in cystic fibrosis: a pilot randomized, controlled trial. European Journal of Clinical Nutrition, 2017, 71, 203-205.	1.3	40
33	IFITM1 targets HIV-1 latently infected cells for antibody-dependent cytolysis. JCI Insight, 2017, 2, e85811.	2.3	10
34	MAIT cells are reduced in frequency and functionally impaired in human T lymphotropic virus type 1 infection: Potential clinical implications. PLoS ONE, 2017, 12, e0175345.	1.1	33
35	T-cell Responses in Individuals Infected with Zika Virus and in Those Vaccinated Against Dengue Virus. Pathogens and Immunity, 2017, 2, 274.	1.4	18
36	Loss of Circulating Mucosal-Associated Invariant T Cells in Common Variable Immunodeficiency Is Associated with Immune Activation and Loss of Eomes and PLZF. ImmunoHorizons, 2017, 1, 142-155.	0.8	8

#	Article	IF	Citations
37	Innate Invariant NKT Cell Recognition of HIV-1â€“Infected Dendritic Cells Is an Early Detection Mechanism Targeted by Viral Immune Evasion. Journal of Immunology, 2016, 197, 1843-1851.	0.4	20
38	Inversion of the VÎ´1 to VÎ´2 Î³Î´ T cell ratio in CVID is not restored by IVIg and is associated with immune activation and exhaustion. Medicine (United States), 2016, 95, e4304.	0.4	10
39	Role of translocated bacterial flagellin in monocyte activation among individuals with chronic HIV-1 infection. Clinical Immunology, 2015, 161, 180-189.	1.4	9
40	Persistent Immune Activation in CVID and the Role of IVIg in Its Suppression. Frontiers in Immunology, 2014, 5, 637.	2.2	37
41	Invariant natural killer T cells in patients with common variable immunodeficiency. Journal of Allergy and Clinical Immunology, 2014, 134, 989-990.	1.5	3
42	Exosomes from breast milk inhibit HIV-1 infection of dendritic cells and subsequent viral transfer to CD4+ T cells. Aids, 2014, 28, 171-180.	1.0	133
43	Technical Advance: Measurement of iNKT cell responses at the single-cell level against rare HIV-1-infected dendritic cells in a mixed culture. Journal of Leukocyte Biology, 2013, 93, 449-455.	1.5	3
44	Dysregulated CD1 profile in myeloid dendritic cells in CVID is normalized by IVIg treatment. Blood, 2013, 121, 4963-4964.	0.6	14
45	IVIg Immune Reconstitution Treatment Alleviates the State of Persistent Immune Activation and Suppressed CD4 T Cell Counts in CVID. PLoS ONE, 2013, 8, e75199.	1.1	47
46	Contact-Dependent Interference with Invariant NKT Cell Activation by Herpes Simplex Virus-Infected Cells. Journal of Immunology, 2012, 188, 6216-6224.	0.4	18
47	Interaction between intravenous immunoglobulin (IVIg) and the low-density lipoprotein receptor-related protein 1: A role for transcytosis across the blood brain barrier?. Journal of Neuroimmunology, 2012, 251, 39-44.	1.1	10
48	Prevention of T cell activation by interference of internalized intravenous immunoglobulin (IVIg) with MHC II-dependent native antigen presentation. Clinical Immunology, 2011, 141, 273-283.	1.4	18
49	NKG2D performs two functions in invariant NKT cells: Direct TCRâ€independent activation of NKâ€like cytolysis and coâ€stimulation of activation by CD1d. European Journal of Immunology, 2011, 41, 1913-1923.	1.6	111
50	Inhibition of B cell-mediated antigen presentation by intravenous immunoglobulins (IVIg). Clinical Immunology, 2010, 135, 422-429.	1.4	44
51	Increased secretion of hyperimmune antibodies following lipopolysaccharide stimulation of CD40â€activated human B cells in vitro. Immunology, 2009, 126, 588-595.	2.0	19
52	Spontaneous internalization of IVIg in activated B cells. Immunology Letters, 2009, 124, 18-26.	1.1	23
53	Dose-Dependent Inhibition of BrdU Detection in the Cell Proliferation ELISA by Culture Medium Proteins. Journal of Immunoassay and Immunochemistry, 2009, 30, 348-357.	0.5	7